Linezolid

Related Experiment Video

Updated: Oct 9, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

G French1

  • 1Department of Infection, St Thomas' Hospital, London, UK.

International Journal of Clinical Practice
|February 24, 2001
PubMed

Insights

Linezolid, a novel oxazolidinone antibiotic, shows efficacy against multidrug-resistant Gram-positive bacteria, including hospital-acquired infections. Its favorable pharmacokinetics and safety profile make it a promising option for treating resistant infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Rising global antibiotic resistance in Gram-positive bacteria, particularly in hospital settings.
  • Emergence of vancomycin-resistant enterococci and vancomycin-intermediate Staphylococcus aureus necessitates new therapeutic options.
  • Glycopeptides like vancomycin are often last-resort treatments for resistant Gram-positive infections.

Purpose of the Study:

  • To introduce linezolid, a novel oxazolidinone antibiotic, as a potential treatment for multidrug-resistant Gram-positive bacteria.
  • To highlight linezolid's activity against clinically significant resistant Gram-positive pathogens.
  • To review linezolid's pharmacokinetic properties, safety profile, and clinical trial outcomes.

Main Methods:

  • Review of linezolid's chemical properties and mechanism of action.
  • Analysis of in vitro activity against resistant Gram-positive strains.
  • Evaluation of pharmacokinetic data, including bioavailability and dosing considerations.
  • Summary of clinical trial results for various infection types.

Main Results:

  • Linezolid demonstrates broad-spectrum activity against all clinically important Gram-positive bacteria, including resistant strains.
  • The drug exhibits favorable pharmacokinetics with equal oral and intravenous bioavailability and no renal dose adjustment needed.
  • Clinical trials show excellent efficacy in treating skin and soft tissue, respiratory, and bloodstream infections.
  • Linezolid possesses a good safety profile.

Conclusions:

  • Linezolid represents a significant advancement in the treatment of multidrug-resistant Gram-positive bacterial infections.
  • Its efficacy, safety, and pharmacokinetic advantages position it as a valuable therapeutic agent.
  • Combined with infection control and judicious antibiotic stewardship, linezolid can aid in combating resistant Gram-positive bacteria.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Amplicon Sequencing using the Long-Read Sequencing Technologies08:57

Amplicon Sequencing using the Long-Read Sequencing Technologies

Published on: August 29, 2025

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...